secwatch.observer — SEC 8-K summary
======================================

Issuer:     Silo Pharma, Inc. (SILO)
CIK:        0001514183
Form:       8-K
Filed at:   2024-09-10T23:59:59+00:00
Accession:  0001213900-24-077111
Event type: other
Sentiment:  neutral
Materiality: 0.20
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Silo Pharma posts investor presentation for Sep 2024 conference; notes SPC-15 pre-IND submitted
--------------------------------------------------------------------------------

- Presentation used at H.C. Wainwright 26th Annual Global Investment Conference on Sep 10, 2024.
- Lead asset SPC-15 (intranasal PTSD treatment) pre-IND submitted for first-in-human trials.
- Pipeline also includes SP-26 (ketamine implant for fibromyalgia), SPC-14 (Alzheimer's), SPU-16 (MS).
- Exclusive licenses from Columbia University (SPC-15, SPC-14) and University of Maryland (SPU-16).
- Company intends to use 505(b)(2) regulatory pathway for SPC-15 and SP-26 to shorten timelines.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1514183/000121390024077111/0001213900-24-077111-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1514183/000121390024077111/ea0213917-8k_silopharma.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-077111

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer